Breaking News, Trials & Filings

Theravance Initiates Study in ALI caused by COVID-19

TD-0903 has potential to inhibit cytokine storm associated with ALI and prevent progression to Acute Respiratory Distress Syndrome

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Theravance Biopharma, Inc. has initiated a Phase I study of TD-0903, a lung-selective, nebulized Janus kinase inhibitor (JAKi) in development for the potential treatment of hospitalized patients with Acute Lung Injury (ALI) caused by COVID-19. TD-0903 has the potential to inhibit the cytokine storm associated with ALI and prevent progression to Acute Respiratory Distress Syndrome (ARDS). The study will assess the safety, tolerability and pharmacokinetics of single- and multiple-ascending dose...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters